{
    "xml": "<topic id=\"PHP2321\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/zuclopenthixol-decanoate\" basename=\"zuclopenthixol-decanoate\" title=\"ZUCLOPENTHIXOL DECANOATE\">\n<title>ZUCLOPENTHIXOL DECANOATE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_390\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/thioxanthenes/zuclopenthixol\">Zuclopenthixol</xref>\n</p>\n<data name=\"vtmid\">321707006</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_716774613\" title=\"Antipsychotics (first-generation, depot injections)\">Antipsychotics (first-generation, depot injections)</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" title=\"ANTIPSYCHOTIC DRUGS\" namespace=\"/drug-classes/antipsychotic-drugs\">ANTIPSYCHOTIC DRUGS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP62319\" outputclass=\"indicationsAndDose\" rev=\"1.25\" parent=\"/drugs/zuclopenthixol-decanoate\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Maintenance in schizophrenia and paranoid psychoses</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By deep intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Test dose 100&#8239;mg, dose to be administered into the upper outer buttock or lateral thigh, followed by 200&#8211;500&#8239;mg after at least 7&#8239;days, then 200&#8211;500&#8239;mg every 1&#8211;4&#8239;weeks, adjusted according to response, higher doses of more than 500mg can be used; do not exceed 600&#8239;mg weekly.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Elderly</p>\n<p>A quarter to half usual starting dose to be used.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62439\" outputclass=\"importantSafetyInformation\" rev=\"1.8\" parent=\"/drugs/zuclopenthixol-decanoate\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p>When prescribing, dispensing, or administering, check that this is the correct preparation&#8212;this preparation is used for <i>maintenance</i> treatment and should <b>not</b> be used for the short-term management of an <i>acute episode</i>.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62456\" outputclass=\"contraindications\" rev=\"1.12\" parent=\"/drugs/zuclopenthixol-decanoate\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Children</ph>; <ph outputclass=\"contraindication\">CNS depression</ph>; <ph outputclass=\"contraindication\">comatose states</ph>; <ph outputclass=\"contraindication\">phaeochromocytoma</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62473\" outputclass=\"cautions\" rev=\"1.23\" parent=\"/drugs/zuclopenthixol-decanoate\">\n<title>Cautions</title>\n<body>\r\n<section outputclass=\"cautions\">\r\n<p>\r\n<ph outputclass=\"caution\">Avoid in <xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>\r\n</ph>; <ph outputclass=\"caution\">QT interval prolongation</ph>; <ph outputclass=\"caution\">when transferring from oral to depot therapy, the dose by mouth should be reduced gradually</ph>\r\n</p>\r\n </section>\r\n\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP62304\" outputclass=\"interactions\" rev=\"1.9\" parent=\"/drugs/zuclopenthixol-decanoate\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Avoid concomitant use of drugs that prolong QT interval.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62231\" outputclass=\"sideEffects\" rev=\"1.9\" parent=\"/drugs/zuclopenthixol-decanoate\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Erythema</ph>; <ph outputclass=\"sideEffect\">nodules</ph>; <ph outputclass=\"sideEffect\">pain at injection site</ph>; <ph outputclass=\"sideEffect\">swelling</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p>If the dose needs to be reduced to alleviate side-effects, it is important to recognise that the plasma-drug concentration may not fall for some time after reducing the dose, therefore it may be a month or longer before side-effects subside.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62279\" outputclass=\"pregnancy\" parent=\"/drugs/zuclopenthixol-decanoate\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p>\n<p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62482\" outputclass=\"breastFeeding\" parent=\"/drugs/zuclopenthixol-decanoate\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant.</p>\n<p>Animal studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.</p>\n<p>Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62406\" outputclass=\"hepaticImpairment\" parent=\"/drugs/zuclopenthixol-decanoate\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Can precipitate coma.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62256\" outputclass=\"renalImpairment\" parent=\"/drugs/zuclopenthixol-decanoate\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Start with small doses in severe renal impairment because of increased cerebral sensitivity.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62180\" outputclass=\"monitoringRequirements\" parent=\"/drugs/zuclopenthixol-decanoate\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Treatment requires careful monitoring for optimum effect.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62508\" outputclass=\"directionsForAdministration\" rev=\"1.11\" parent=\"/drugs/zuclopenthixol-decanoate\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>In general not more than 2&#8211;3&#8239;mL of oily injection should be administered at any one site.</p>\n<p>Correct injection technique (including use of z-track technique) and rotation of injection sites are essential.</p>\n<p>When initiating therapy with sustained-release preparations of conventional antipsychotics, patients should first be given a small test-dose as undesirable side-effects are prolonged.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP2321-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/zuclopenthixol-decanoate\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77866\" title=\"Solution for injection\" namespace=\"/drugs/zuclopenthixol-decanoate/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78155\" namespace=\"/treatment-summaries/psychoses-and-related-disorders\" title=\"Psychoses and related disorders\" count=\"1\" rel=\"backlink\">Psychoses and related disorders</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_390\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/thioxanthenes/zuclopenthixol\" title=\"Zuclopenthixol\" count=\"1\" rel=\"link\">Zuclopenthixol</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" namespace=\"/drug-classes/antipsychotic-drugs\" title=\"ANTIPSYCHOTIC DRUGS\" count=\"1\" rel=\"link\">ANTIPSYCHOTIC DRUGS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78608\" namespace=\"/treatment-summaries/acute-porphyrias\" title=\"Acute porphyrias\" count=\"1\" rel=\"link\">Acute porphyrias</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77866\" namespace=\"/drugs/zuclopenthixol-decanoate/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP2321",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/zuclopenthixol-decanoate",
    "basename": "zuclopenthixol-decanoate",
    "title": "ZUCLOPENTHIXOL DECANOATE",
    "interactants": [
        {
            "id": "bnf_int_390",
            "label": "Zuclopenthixol"
        }
    ],
    "vtmid": "321707006",
    "drugClassification": [
        "Antipsychotics (first-generation, depot injections)"
    ],
    "inheritsFromClass": [
        "ANTIPSYCHOTIC DRUGS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Maintenance in schizophrenia and paranoid psychoses",
                        "html": "Maintenance in schizophrenia and paranoid psychoses"
                    }
                ],
                "specificity": {
                    "routes": [
                        "deep intramuscular injection"
                    ],
                    "textContent": "By deep intramuscular injection",
                    "html": "By deep intramuscular injection"
                },
                "adult": [
                    {
                        "textContent": "Test dose 100 mg, dose to be administered into the upper outer buttock or lateral thigh, followed by 200&#8211;500 mg after at least 7 days, then 200&#8211;500 mg every 1&#8211;4 weeks, adjusted according to response, higher doses of more than 500mg can be used; do not exceed 600 mg weekly.",
                        "html": "<p>Test dose 100&#8239;mg, dose to be administered into the upper outer buttock or lateral thigh, followed by 200&#8211;500&#8239;mg after at least 7&#8239;days, then 200&#8211;500&#8239;mg every 1&#8211;4&#8239;weeks, adjusted according to response, higher doses of more than 500mg can be used; do not exceed 600&#8239;mg weekly.</p>"
                    },
                    {
                        "textContent": "A quarter to half usual starting dose to be used.",
                        "html": "<p>A quarter to half usual starting dose to be used.</p>",
                        "ageGroup": "elderly"
                    }
                ]
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "textContent": "When prescribing, dispensing, or administering, check that this is the correct preparation&#8212;this preparation is used for maintenance treatment and should not be used for the short-term management of an acute episode.",
                "html": "<p>When prescribing, dispensing, or administering, check that this is the correct preparation&#8212;this preparation is used for <i>maintenance</i> treatment and should <b>not</b> be used for the short-term management of an <i>acute episode</i>.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Children",
                "html": "Children"
            },
            {
                "type": "contraindications",
                "textContent": "CNS depression",
                "html": "CNS depression"
            },
            {
                "type": "contraindications",
                "textContent": "comatose states",
                "html": "comatose states"
            },
            {
                "type": "contraindications",
                "textContent": "phaeochromocytoma",
                "html": "phaeochromocytoma"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Avoid in Acute porphyrias",
                "html": "Avoid in <xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>",
                "references": [
                    {
                        "id": "PHP78608",
                        "label": "Acute porphyrias"
                    }
                ]
            },
            {
                "type": "cautions",
                "textContent": "QT interval prolongation",
                "html": "QT interval prolongation"
            },
            {
                "type": "cautions",
                "textContent": "when transferring from oral to depot therapy, the dose by mouth should be reduced gradually",
                "html": "when transferring from oral to depot therapy, the dose by mouth should be reduced gradually"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Avoid concomitant use of drugs that prolong QT interval.",
                "html": "<p>Avoid concomitant use of drugs that prolong QT interval.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Erythema",
                        "html": "Erythema",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nodules",
                        "html": "nodules",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pain at injection site",
                        "html": "pain at injection site",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "swelling",
                        "html": "swelling",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "textContent": "If the dose needs to be reduced to alleviate side-effects, it is important to recognise that the plasma-drug concentration may not fall for some time after reducing the dose, therefore it may be a month or longer before side-effects subside.",
                "html": "<p>If the dose needs to be reduced to alleviate side-effects, it is important to recognise that the plasma-drug concentration may not fall for some time after reducing the dose, therefore it may be a month or longer before side-effects subside.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.\n\nFollowing maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.",
                "html": "<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p><p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant.\n\nAnimal studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.\n\nChronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.",
                "html": "<p>There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant.</p><p>Animal studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.</p><p>Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Can precipitate coma.",
                "html": "<p>Can precipitate coma.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Start with small doses in severe renal impairment because of increased cerebral sensitivity.",
                "html": "<p>Start with small doses in severe renal impairment because of increased cerebral sensitivity.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Treatment requires careful monitoring for optimum effect.",
                "html": "<p>Treatment requires careful monitoring for optimum effect.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "In general not more than 2&#8211;3 mL of oily injection should be administered at any one site.\n\nCorrect injection technique (including use of z-track technique) and rotation of injection sites are essential.\n\nWhen initiating therapy with sustained-release preparations of conventional antipsychotics, patients should first be given a small test-dose as undesirable side-effects are prolonged.",
                "html": "<p>In general not more than 2&#8211;3&#8239;mL of oily injection should be administered at any one site.</p><p>Correct injection technique (including use of z-track technique) and rotation of injection sites are essential.</p><p>When initiating therapy with sustained-release preparations of conventional antipsychotics, patients should first be given a small test-dose as undesirable side-effects are prolonged.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77866",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78155",
                "label": "Psychoses and related disorders",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_390",
                "label": "Zuclopenthixol",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34569",
                "label": "ANTIPSYCHOTIC DRUGS",
                "type": "drugClass"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78608",
                "label": "Acute porphyrias",
                "type": "treatmentSummary"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77866",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}